Abstract
Cancer is the result of cumulative multiple genetic mutations, which result in the activation of oncogenes and / or the inactivation of tumor suppressor genes. Current theories of malignant transformation postulate that the development of primary brain tumors is the consequence of the sequential accumulation of multiple genetic alterations in brain cells, each of which contributes to the induction of a progressively more malignant phenotype. Traditionally, our understanding of brain tumor biology has come from the study of single specific genes or chromosome regions at a time. Although several genetic aberrations and gene expression changes have been identified using such focused techniques, the traditional methods of cancer research are tediously slow and provide limited insight into the global gene expression patterns that occur during the malignant transformation, development, and progression of primary brain cancers. Because hundreds of genes may be simultaneously involved in the mechanisms of ca rcinogenesis, new genomic high-throughput technologies have recently come into the forefront of cancer research. These technologies, which include cDNA and oligonucleotide microarrays (gene chips) and tissue microarray (tissue chip) techniques, may considerably facilitate the molecular profiling of human tumors. Such molecular fingerprinting of malignant gliomas, for example, may lead to advances in diagnosis, prognosis, and design of novel therapeutic approaches that could improve the clinical outcome of patients suffering from this rapidly fatal disease. This review will describe the principles of microarray technology as applied to human brain tumor research, summarize its use and limitations in identifying brain tumor-associated genes thus far, and speculate on the future applications and clinical ramifications of such genomic large-scale screening techniques in neuro-oncology.
Keywords: Microarrays, Brain Tumors, cancer, cdna microarrays, tissue microarray tma analysis, insulin-like growth, protein2 1gfbp2, facetor binding gene
Current Genomics
Title: Microarrays and the Genetic Analysis of Brain Tumors
Volume: 3 Issue: 1
Author(s): L. M. Liau and I. Yang
Affiliation:
Keywords: Microarrays, Brain Tumors, cancer, cdna microarrays, tissue microarray tma analysis, insulin-like growth, protein2 1gfbp2, facetor binding gene
Abstract: Cancer is the result of cumulative multiple genetic mutations, which result in the activation of oncogenes and / or the inactivation of tumor suppressor genes. Current theories of malignant transformation postulate that the development of primary brain tumors is the consequence of the sequential accumulation of multiple genetic alterations in brain cells, each of which contributes to the induction of a progressively more malignant phenotype. Traditionally, our understanding of brain tumor biology has come from the study of single specific genes or chromosome regions at a time. Although several genetic aberrations and gene expression changes have been identified using such focused techniques, the traditional methods of cancer research are tediously slow and provide limited insight into the global gene expression patterns that occur during the malignant transformation, development, and progression of primary brain cancers. Because hundreds of genes may be simultaneously involved in the mechanisms of ca rcinogenesis, new genomic high-throughput technologies have recently come into the forefront of cancer research. These technologies, which include cDNA and oligonucleotide microarrays (gene chips) and tissue microarray (tissue chip) techniques, may considerably facilitate the molecular profiling of human tumors. Such molecular fingerprinting of malignant gliomas, for example, may lead to advances in diagnosis, prognosis, and design of novel therapeutic approaches that could improve the clinical outcome of patients suffering from this rapidly fatal disease. This review will describe the principles of microarray technology as applied to human brain tumor research, summarize its use and limitations in identifying brain tumor-associated genes thus far, and speculate on the future applications and clinical ramifications of such genomic large-scale screening techniques in neuro-oncology.
Export Options
About this article
Cite this article as:
Liau M. L. and Yang I., Microarrays and the Genetic Analysis of Brain Tumors, Current Genomics 2002; 3 (1) . https://dx.doi.org/10.2174/1389202023350633
DOI https://dx.doi.org/10.2174/1389202023350633 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Towards More Successful Gene Therapy Clinical Trials for β-Thalassemia
Current Molecular Medicine Subject Index To Volume 12
Current Pharmaceutical Design Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature
Current Cardiology Reviews Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Radiolabeled Glucose Derivatives for Tumor Imaging Using SPECT and PET
Current Medicinal Chemistry The Hippocampal Autophagic Machinery is Depressed in the Absence of the Circadian Clock Protein PER1 that may Lead to Vulnerability During Cerebral Ischemia
Current Neurovascular Research Molecular Markers of Glial Tumors: Current Targeting Strategies
Current Medicinal Chemistry Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination
Anti-Cancer Agents in Medicinal Chemistry Cell-Based Assay System to Estimate the Effect of 125I Seeds on Cancer Cells: Effect of Osteopontin
Recent Patents on Anti-Cancer Drug Discovery Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Local Gene Delivery for Cancer Therapy
Current Gene Therapy Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design